1 In primary unpassaged rat brain capillary endothelial cell cultures (RBECs), using reversetranscriptase PCR with primers speci®c for P2Y receptor subtypes, we detected mRNA for P2Y 2 , P2Y 4 and P2Y 6 , but not P2Y 1 receptors. 2 None of the various nucleotides tested reduced forskolin elevated cyclic AMP levels in RBECs. ATP and ATPgS, as well as adenosine, enhanced cyclic AMP accumulation in the presence of forskolin.
Introduction
Extracellular nucleotides such as ATP, ADP, UTP and UDP exert diverse eects on cellular function by acting on two subfamilies of P2 receptors, the intrinsic ion channel P2X receptors and the G protein-coupled P2Y receptors (Fredholm et al., 1997) . The mammalian P2Y receptor subfamily currently comprises ®ve cloned members (P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 and P2Y 1 ). One of the challenges of this emerging pharmacology is to relate the mechanism of action of individual members to the functional responses of cells through an understanding of the second messenger systems recruited. All of these ®ve receptors have been described as coupled to phosphoinositide-speci®c phospholipase C (PLC) Boarder & Hourani, 1998) , and much of their action at dierent cellular sites has been interpreted as downstream of PLC. The reports of cloned receptors have revealed little evidence for direct regulation of cyclic AMP, with the exception of the P2Y 11 receptor which has been shown to couple to stimulation of adenylyl cyclase as well as PLC (Communi et al., 1997) . However, there are various reports of agonists at P2Y receptors in native systems eliciting a change in cyclic AMP. Best established is inhibition of cyclic AMP synthesis by P2 receptors in platelets (Hourani & Hall, 1994) , hepatocyes (Tomura et al., 1992) , C6 glioma cells (Schachter et al., 1996) , Schwann cells (Berti-Mattera et al., 1996) and a clonal brain endothelial cell (Webb et al., 1996; Hechler et al., 1998a,b) . The molecular nature of the negative cyclase-coupled receptors is not securely de®ned. In addition, native systems provide several examples of stimulation of P2Y receptors which result in sensitization of cyclic AMP responses to either other agonists acting at G s -coupled receptors or to forskolin. Such sensitization may be direct or it may be downstream of PLC and the activation of protein kinase C (Boarder et al., 1988) . Following a report of sensitization by extracellular ATP in microvascular endothelial cells (Allsup & Boarder, 1991) evidence was presented which was consistent with a direct sensitization of adenylyl cyclase by P2 receptors (Johnson et al., 1991) . This was followed by a reported synergistic action by ATP with forskolin in aortic endothelial cells (Cote et al., 1993) .
Regulation of [Ca 2+ ] i and cyclic AMP are central to the control of brain microvascular permeability (Rubin et al., 1991; . Brain capillary endothelial cells form a regulated blood-brain-barrier under the in¯uence of diusable mediators from astrocytes. The nature and mechanisms of action of these mediators are unclear, but candidates include the nucleotides. In 1991 it was shown that ATP increases [Ca cells (e.g. Nobles et al., 1995) . The P2Y 1 -like receptor was unusual in that it lead to an increase in [Ca 2+ ] i by mobilization of intracellular stores in the apparent absence of a PLC response (Vigne et al., 1994; Albert et al., 1997) . In a clonal cell line derived from RBECs (B10) it has also been reported (Webb et al., 1996) that a P2Y receptor is coupled to the inhibition of adenylyl cyclase. We found no evidence of inhibition of adenylyl cyclase by P2Y receptors, but did report a substantial increase in accumulation of cyclic AMP in response to ATP, in the presence of a concentration of forskolin which produced only a small eect on its own (Albert et al., 1997) . This led to the studies in the present report investigating the possibility that P2Y receptors can sensitize the adenylyl cyclase response to forskolin in native RBEC cultures.
Methods

Cell culture
The rat brain capillary endothelial cells (RBECs) were prepared and cultured as described in Albert et al. (1997) . Brie¯y, the cell culture was grown out from a puri®ed preparation of rat brain cortical capillaries plated directly into 96-well plates or T25 asks. The culture medium was MEM-D-Val with 20% foetal calf serum, penicillin (100 iu ml 71 ), streptomycin (100 mg ml 71 ), glutamine (27 mg ml 71 ) and 75 mg ml 71 endothelial cell growth supplement (Sigma E-2759). The preparation was an almost completely homogenous culture of microvascular endothelial cells exhibiting a diuse immunoreactivity for factor VIII. Cells were used at con¯uence in 96-well plates for the cyclic AMP assay and mRNA was extracted from con¯uent T25¯asks for the RT ± PCR.
Cyclic AMP assay
For the cyclic AMP assay 96-well multiwells were transferred to a 378C water bath, growth medium aspirated, and replaced with 50 ml balanced salt solution (BSS, composition in (mM): NaCl 125, KCl 5.4, NaHCO 3 16.2, HEPES 30, NaH 2 PO 4 1, MgSO 4 0.8, CaCl 2 1.8, glucose 5.5, pH 7.4). After 30 min a further 50 ml of BSS was added containing, where appropriate, a 2 fold ®nal concentration of antagonists or inhibitors, followed 10 min later with 20 ml of 6 fold ®nal concentration of agonists and forskolin. The incubation was stopped, after 5 min except where indicated otherwise, by addition of 40 ml of 2 M trichloroacetic acid. Cyclic AMP was measured in these trichloroacetic acid extracts after neutralization with ether or freon:octylamine extraction and addition of NaHCO 3 , by use of the protein binding assay (Brown et al., 1971) .
Reverse transcriptase ± polymerase chain reaction (RT ± PCR)
The RT ± PCR for P2Y 1 , P2Y 2 , P2Y 4 and P2Y 6 mRNA were carried out exactly as described earlier (Harper et al., 1998) . Each run included a positive control to which was added 5 ng of plasmid DNA containing the whole coding region of the appropriate P2Y receptor. To check for contamination with genomic DNA each run also included ®rst strand synthesis in the absence of reverse transcriptase.
Statistical analysis
Statistical analyses were with Graph-Pad Prism2 (Graphpad Software Inc., San Diego, CA, U.S.A.).
Materials
Cell culture supplies were from GIBCO (Paisley, Scotland 
Results
RT ± PCR of RBECs
To understand the potential for P2 nucleotide receptor regulation of cyclic AMP in RBECs by the four P2Y receptor subtypes for which sequences were available for the rat, RNA was extracted from 25 cm 2¯a sks of unpassaged brain endothelial cells, cDNA synthesized and used as template for PCR employing primers designed to speci®cally amplify regions encoding for rat P2Y 1 , P2Y 2 , P2Y 4 and P2Y 6 receptors. In each case ampli®cation of the brain endothelial cell cDNA template was in parallel with ampli®cation of the cognate receptor DNA sequence in a plasmid containing the whole coding region of each receptor. This provided a positive control for the ampli®cation procedure. Ampli®cation products were detected for P2Y 2 , P2Y 4 and P2Y 6 (Figure 1 ) upon RT ± PCR from RNA preparations from three separate cell preparations. These products were cloned and sequenced to con®rm their identity. Ampli®cation of the P2Y 1 receptor mRNA was not detected.
Purinergic regulation of cyclic AMP in RBECs: eect of forskolin and phosphodiesterase inhibitors
In initial experiments studying cyclic AMP responses to purinergic agonists in RBECs cells were preincubated with IBMX (10 min) followed by 5 min stimulation with nucleotides in the presence of IBMX. Under these conditions the nucleotides had no eect on the levels of cyclic AMP, although forskolin in the presence of IBMX gave a very large increase in cyclic AMP levels (Table 1A) . This forskolin and IBMX elevated cyclic AMP accumulation was not aected by 300 mM ATP (not shown). The nucleotides had no eect in the absence of forskolin and IBMX (Table 1A and Figure 2) .
To see whether the lack of eect of nucleotides on cyclic AMP was related to the presence of IBMX in some of the experiments described above, we sought conditions of phosphodiesterase (PDE) inhibition in the absence of a methylxanthine inhibitor. We tried the PDE 3 inhibitor siguazadon and the PDE 4 inhibitor Ro-20 1724. Siguazadon at 10 mM and Ro-20 1724 at 50 mM, either alone or together, did not lead to the substantial elevation of cyclic AMP levels by forskolin seen with IBMX (Table 1B) . The combination of siguazadon and Ro-20 1724 therefore failed to provide suitable conditions for investigating regulation of cyclic AMP synthesis.
We then asked whether nucleotides could reduce forskolin elevated cyclic AMP levels in the absence of PDE inhibition. Figure 2A shows the eect of ATP on the response to increasing concentrations of forskolin. In the absence of PDE inhibition there was a modest increase in response to forskolin. Rather than attenuating this, the presence of ATP led to an unexpected and very substantial potentiation of the response to forskolin at levels of 5 mM and above. This stimulation of cyclic AMP levels by ATP did not occur at 0.1 mM forskolin, and was modest at 1 mM forskolin. Cells stimulated with 300 mM ATP in the presence of 5 mM forskolin for dierent periods of time showed a clear increase after 1 min, with the accumulation of cyclic AMP increasing in an approximately linear manner for up to 15 min (not shown). Subsequent experiments were with 5 min incubations except where indicated otherwise.
The eect of ATP, UTP, ATPgS and 2MeSATP on cyclic AMP levels in the presence and absence of forskolin are shown in Figure 2B . Responses to 300 mM UTP or 300 mM 2MeSATP in the presence of 5 mM forskolin were small compared to those of 300 mM ATP or ATPgS. All of these agonists elicit Ca 2+ responses at these concentrations in these cells (Albert et al., 1997) . UDP also failed to give a substantial stimulation in the presence of 5 mM forskolin (data not shown). Figure 3 shows the eect of increasing concentrations of ATP, UTP and a,b-methylene ATP. Typically the response to ATP shows signs of plateau between 100 and 300 mM (three out of four in this group of experiments). When the results from this series of experiments were pooled, and calculated on the assumption that the response at 300 mM was the maximum tissue response to ATP, then the apparent 7log EC 50 for ATP was 4.02+0.66 (n=4). From Figure 3 it can also be seen that there was no substantial response to UTP or a,b-methylene ATP at any of the concentrations tested.
Adenosine gave similar responses to those of ATP and ATPgS in the presence of 5 mM forskolin (Figure 4 ). Pooled data of paired experiments showed that the responses to 5 min stimulations with 300 mM adenosine or ATPgS were 138+25 and 139+51%, respectively, of that of ATP (no signi®cant dierence by paired t-test). The apparent EC 50 values for the three agonists were also very similar. This is shown in Figure 4 B,D,F. Apparent 7log EC 50 values pooled across experiments were 4.26+0.71 (n=4) for ATPgS, and 4.49+0.24 (n=4) for adenosine.
Response to ATP is not exclusively dependent on conversion to adenosine
If the responses to ATP and ATPgS were due solely to breakdown to adenosine we might expect that with shorter The PDE inhibitors IBMX (300 mM), siguazadon (10 mM) and Ro-20 1724 (50 mM) were present for 10 min prior to and during the uncubation (5 min) with ATP (300 mM) or forskolin (5 mM). Data are pmols per well of cyclic AMP, mean+s.e.mean (n=3 or 4). incubation times the response to ATPgS would be smaller than that of ATP, and that the size of the responses to ATP and ATPgS would be reduced compared to adenosine. Figure 4 shows a series of experiments in which the responses to the three agonists were compared with 1 min (left panels) and 5 min (right panels) incubation times. In each case the size of the response at 1 min was smaller than that at 5 min, but in each case the size of response at 1 min was the same for all three agonists. There was no change in EC 50 resulting from the dierence in incubation times.
To further address the question of whether the response to ATP was mediated by conversion to adenosine we used adenosine deaminase to remove adenosine formed during the incubation. The response to 300 mM adenosine was completely eliminated in the presence of 2 units ml 71 of adenosine deaminase (data not shown). Over four experiments the response to 300 mM ATP was reduced to 59.2+11.0% by adenosine deaminase. This is illustrated in Figure 5 , which also shows the antagonism by 8-sulphophenyltheophylline (8-SPT) of the response to ATP and of the residual response to ATP in the presence of adenosine deaminase. Both show eectively complete antagonism by 300 mM 8-SPT, with an IC 50 similar to that which we see with adenosine, of 10 ± 30 mM.
Eects of adenosine receptor agonists and antagonists
We undertook further studies with agonists and antagonists known to act at adenosine receptors, not only to characterize the response to adenosine but also to see if the pharmacology of the response to ATP was divergent from that of responses to adenosine. Figure 6 shows the eect of stimulation with 2-chloradenosine (agonist at A 1 , A 2A and A 2B receptors), the A 1 selective agonist CCPA and the A 2A selective agonist CGS 21680. While 2-chloradenosine gave a robust response, neither CCPA nor CGS 21680, in a range of concentrations at which they are eective agonists at A 1 and A 2A receptors, gave any response to all. The non-selective agonist NECA also elicited a response, of similar magnitude to that of ATP, which was maximal at 10 mM (not shown).
We investigated the eect of a series of antagonists present for 10 min before and during the incubation with adenosine or ATP (both at 300 mM). The non-selective antagonists IBMX (300 mM) and 8-SPT ( Figure 5 ) were eective at blocking the responses to both adenosine and ATP, as described above. However, the presence of the antagonist DPCPX and the A 2A selective antagonist SCH 58261, each at concentrations up to 1 mM, had no eect on the responses to stimulation with 300 mM adenosine or ATP (not shown).
Eect of cyclo-oxygenase inhibition
To determine whether the stimulation of cyclic AMP levels was secondary to the formation of cyclo-oxygenase products such as prostaglandins we stimulated the cells in the presence of 1 mM indomethacin. Results from a representative experiment are shown in Table 2 . ATP, ATPgS and adenosine gave substantial stimulations of cyclic AMP accumulation in the presence of 5 mM forskolin. In each case this was unaected by the presence of indomethacin. Pooled over three separate experiments (each in quadruplicate) with dierent cell preparations the stimulation by ATP (300 mM) plus forskolin (5 mM) in the presence of 1 mM indomethacin was 96.5+8.4% of the stimulation in the absence of indomethacin.
Discussion
In brain capillary endothelial cells regulation of cyclic AMP level by nucleotides is complicated by the existence of multiple P2 receptors, and by the use of dierent types of brain capillary cell cultures in dierent laboratories. Webb et al. (1996) , using a clonal cell line (B10) of rat brain capillary endothelial cells, describe an inhibition of cyclic AMP on stimulation of a P2Y receptor. In the unpassaged brain capillary endothelial cultures (RBECs) we have previously reported that 2MeSATP does not reduce cyclic AMP levels which have been raised by forskolin (Albert et al., 1997) . This implies that the inhibition of cyclic AMP synthesis by P2Y 1 receptors seen in transfected 1321N1 cells (our unpublished data) does not occur in RBEC cultures. The RT ± PCR work described here reinforces this view. There was no detectable expression of mRNA for P2Y 1 receptors, while sequences encoding P2Y 2 , P2Y 4 and P2Y 6 receptors were easily detected. We conclude from this that P2Y 1 receptors do not regulate unpassaged cells, and in particular they do not regulate cyclic AMP in these cells, and that the [Ca 2+ ] i response to 2MeSATP and ADP seen in the absence of a detectable phosphoinositide response in these unpassaged cell cultures (Albert et al., 1997) is not at a P2Y 1 receptor.
The presence of mRNA encoding P2Y 4 and P2Y 6 receptors indicate a potential for P2Y mediated, forskolin-dependent, stimulations of cyclic AMP. However, the elevations of cyclic AMP by ATP seen here do not have the characteristics consistent with the currently cloned P2Y receptors. Firstly, stimulation cannot be seen in the presence of IBMX. Secondly, 8-SPT is an eective antagonist. This excludes, not only the P2Y 1 , P2Y 2 , P2Y 4 and P2Y 6 receptors described above, but also the P2Y 11 receptor, which appears to be a candidate for an ATP receptor coupled to adenylyl cyclase, since 8-SPT is not an antagonist at P2Y 11 receptors (Communi et al., 1997) . The failure of either UTP or UDP to stimulate the cyclic AMP response seen with ATP is another indication that neither P2Y 2 , P2Y 4 or P2Y 6 are involved. For this reason no further work with antagonists directed at P2 receptors was undertaken.
The observation that both ATP and adenosine are able to stimulate cyclic AMP accumulation raises the possibility that ATP is acting by conversion to adenosine and subsequent stimulation of G s -coupled A 2 receptors. We report here various observations which make this unlikely. Both adenosine and ATPgS had the same potency as ATP. This was true for both 1 min and 5 min stimulations. If the rate of conversion of ATP to adenosine was suciently rapid as to be complete in less than 1 min of incubation, then ATP could have the same potency even if it had no action of its own. However, this cannot be true of the ectonucleotide resistant analogue ATPgS, even taking into account that it is not completely resistant to breakdown and that it is not completely pure. Impurities (e.g. ATP/ADP) would have to account for the majority of the compound if this were the explanation. The comparisons of Indomethacin (100 mM) and was present for 10 min before and during the 5 min incubation with agonists (all at 300 mM). Forskolin (5 mM) was present with each of the agonists. Data are mean+s.e.mean of cyclic AMP content (pmole per well), n=3 or 4. There were no signi®cant dierences between the presence and absence of indomethacin.
concentration response curve for these three agonists at 1 min and 5 min (Figure 4) are inconsistent with the hypothesis that stimulation by ATPgS is dependent on breakdown to adenosine. The data indicate the presence of a receptor which responds to ATPgS itself, and not just one which responds to adenosine. The hypothesis that the action of ATP is dependent on conversion to adenosine was further explored with the adenosine deaminase experiments. Removal of adenosine in the bulk phase was complete, as indicated by the elimination of responses to added adenosine, but there was only a partial loss of the response to added ATP. Two hypotheses must be considered. Firstly, that there is a biophase at the cell surface where adenosine formed from ATP reaches a sucient concentration locally to stimulate adenosine receptors before it is metabolized by adenosine deaminase. This is possible, even though we are working with cell monolayers. Secondly, that ATP is partially converted to adenosine, and that both ATP and adenosine act with forskolin to stimulate the accumulation of cyclic AMP. The conversion of ATP to adenosine then only results in a loss of response when the adenosine is removed by adenosine deaminase.
If both adenosine and ATP act at cell surface receptors to stimulate cyclic AMP then the pharmacology of the adenosine portion of the stimulation does not clearly indicate one of the described adenosine receptors (Alexander & Peters, 1998) . A 1 receptors are described as G i/o coupled to inhibition of adenylyl cyclase, and are also excluded because CCPA does not act as an agonist and DPCPX does not act as an antagonist. A 2 receptors are described as coupled to the stimulation of adenylyl cyclase via G s . A 2A receptors are excluded because the selective agonist CGS 21680 does not elicit a response and the responses to ATP and adenosine are not antagonized by SCH58261. Neither is the response blocked by DPCPX. This is an A 2B antagonist with a pA 2 of around seven at cloned and transfected A 2B receptors (Alexander et al., 1996) , so under conditions used in these studies DPCPX would be expected to be an eective antagonist at A 2B receptors. However, these data do not completely exclude a contribution from A 2B receptors.
We conclude that the stimulation by ATP of cyclic AMP levels in RBECs is not at known P2Y receptors, and neither is it likely to be completely dependent on conversion to adenosine and action at known P1 receptors. The answer could lie in the form of separate receptors for adenosine and ATP, although the results here are inconsistent with a contribution from known P2 receptors. If two receptors are responsible, there is the potential for complex interactions between the receptors and their signalling pathways in the generation of the data reported here. An alternative explanation is that the response is at a common receptor for ATP and adenosine, as proposed for presynaptic regulation of noradrenaline release from peripheral nerve terminals (Shinozuka et al., 1988; Kurz et al., 1993; Smith et al., 1997) and stimulation of adenylyl cyclase in NG108-15 cells (Matsuoka et al., 1995) . Conigrave et al. (1998) have recently reported evidence for a novel cyclic AMP-linked P2 receptor which responds to ATP but not UTP. However, this response appears distinct from that described in the present paper in several respects. For example, adenosine is a weak agonist, and the response is enhanced by IBMX and insensitive to 8-SPT. A better ®t with the present series of observations is the forskolin enhanced cyclic AMP response to ATP of bovine aortic endothelial cells (Cote et al., 1993) , where adenosine is an eective agonist, 2MeSATP and UTP are ineective, and ATPgS gives the same response as ATP. This implies that an atypical cyclic AMP elevating response to ATP may occur in diverse endothelial cells.
With respect to the mechanisms by which cyclic AMP is elevated in RBECs on stimulation with ATP, the most likely explanation is augmentation of a G s coupled response by forskolin similar to that reported earlier (Cote et al., 1993, and references therein) . An eect via elevated [Ca 2+ ] i is unlikely, since both UTP and 2MeSATP elevate [Ca 2+ ] i but do not eect cyclic AMP. A further possibility is that phospholipase A 2 is activated by these agonists, leading to the prostaglandindependent stimulation of cyclic AMP. Such a mechanism for nucleotide receptor regulation of cyclic AMP has been described by Post et al. (1996) , who show that indomethacin can block this paracrine pathway for stimulation of adenylyl cyclase. The responses to ATP and adenosine in the brain capillary endothelial cells are seen in the presence of indomethacin, indicating that this is not the pathway for stimulation of cyclic AMP accumulation in these experiments.
In this paper we have shown that the cyclic AMP levels of rat brain capillary endothelial cells, maintained in culture without passage, are regulated by extracellular adenosine and ATP. ATP probably acts in part by conversion to adenosine, but experiments with ATPgS provide evidence that a receptor for nucleotides also contributes to these results. Both agonists act on receptors which have a pharmacology which is distinct from those previously cloned and characterized. The nature of the receptors responsible will be the subject of further investigations. In situ these cells form the blood-brain-barrier by a process maintained by adjacent astrocytes and involving the regulation of cyclic AMP levels. It has previously been shown that the 1321N1 astrocytoma cell line releases ATP in a regulated manner into the medium (Lazarowski et al., 1995) . The results presented here provide further information on the way in which nucleotides released by astrocytes could contribute to the regulation of the blood-brain-barrier. A further understanding of these events will require clari®cation of the receptors involved and study of how the cyclic AMP cascade interacts with other cell signalling pathways, such as the p42 and p44 mitogen activated protein kinases, which are also regulated by P2Y receptors in these endothelial cells (Albert et al., 1997) .
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